A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

Capecitabine is a highly active oral fluoropyrimidine that is an attractive alternative to 5-fluorouracil in colorectal cancer treatment. The current study, undertaken in 27 patients with gastrointestinal tumours, aimed to assess the toxicity and potential for significant pharmacokinetic interaction...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Delord, J P, Pierga, J Y, Dieras, V, Bertheault-Cvitkovic, F, Turpin, F L, Lokiec, F, Lochon, I, Chatelut, E, Canal, P, Guimbaud, R, Mery-Mignard, D, Cornen, X, Mouri, Z, Bugat, R
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2005
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361914/
https://ncbi.nlm.nih.gov/pubmed/15756252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602354
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados